Omalizumab in @entity1 with eosinophilic @entity2883 with XXXX : a 36-month follow-up study.

@entity1712 @entity1 @entity1333 @entity565 @entity229 @entity1109 @entity305 @entity56 @entity4216 @entity2883 @entity230
OBJECTIVE: Eosinophilic @entity2883 with @entity2883 (EGPA) is a systemic @entity1333 characterized by @entity565 and blood @entity1712 , with the lung being the organ most frequently affected. Oral glucocorticoids and/or immunosuppressive drugs are the mainstay therapy of EGPA. Occasional reports suggest that EGPA @entity1 can be treated with omalizumab in addition to conventional therapy to achieve @entity565 control. To investigate the long-term effects of omalizumab in @entity1 with EGPA and @entity565 (2 females, 3 males, age 41-64 years), we carried out a 36-month follow-up observational study. At the time of enrollment, the @entity1 were on maintenance therapy and had moderate to severe @entity56 , @entity1712 and rhinosinusitis. @entity4216 / @entity305 and/or histological evidence of tissue eosinophilic infiltration were also present. METHODS: @entity1 were treated with omalizumab (300-600   mg s.c. every 2-4 weeks) as add-on therapy to @entity229 , inhaled @entity230 and bronchodilators. During omalizumab treatment, spirometry, the @entity565 control test (ACT) score and @entity1712 were evaluated, and @entity229 dosage was recorded. RESULTS: During the 36 months of omalizumab treatment @entity565 progressively improved as indicated by spirometry and the ACT score. @entity1712 progressively decreased. The oral @entity229 dose was reduced or withdrawn during treatment. No adverse events were recorded. CONCLUSIONS: In @entity1 with EGPA and moderate to severe @entity56 , omalizumab can be beneficial and safe. It enables corticosteroid tapering while decreasing @entity1712 and @entity1109 over 36 months.
